Ambit Biosciences garners $49M in Series D

San Diego-based Ambit Biosciences has banked $49.3 million in its fourth venture round, earmarking much of that money for its work developing kinase inhibitors. That's enough money to finance the company's operations through 2009. An open label, dose escalation study of AC220 for acute myeloid leukemia is expected to be completed early next year. CEO Scott Salka told BioWorld that preliminary data for the program was positive.

To date, Ambit has raised $106 million to fund operations. Apposite Capital led the round with MedImmune Ventures, OrbiMed Advisors and others joining in. Ambit was a 2006 Fierce 15 company.

- check out the release for more
- here's the BioWorld article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.